← Who reports today · Health Care
Danaher Corporation (DHR) earnings date & Q3 2026 results
Net earnings
$1,235M
up 36.0% y/y
Sales
$6,554M
up 8.3% y/y
Operating profit
$1,245M
up 7.9% y/y
Next report
~ Jan 27
not announced yet
The quarter in brief
Danaher's Q3 2026 sales rose 8.3% to $6,554 million and operating profit grew 7.9% to $1,245 million. Net earnings jumped 36.0% to $1,235 million, or $1.75 per diluted share versus $1.27.
Key growth driver: Q3 included $513 million of amortization of acquisition-related intangibles versus $433 million, an $84 million inventory fair value adjustment and a $52 million… · by the Q3 2026 report
All figures in $M.
| Line item | Amount and change |
|---|---|
| Sales | $6,554 · +8.3% |
| Cost of sales | $2,717 · +7.4% |
| Gross profit | $3,837 · +8.9% · 58.5% margin |
| Selling, general and administrative expenses | $2,159 · +8.4% |
| Research and development expenses | $433 · +14.6% |
| Operating profit | $1,245 · +7.9% · 19.0% margin |
| Other income (expense), net | $9 · −35.7% |
| Interest expense | $135 · +101% |
| Interest income | $31 · +933% |
| Earnings before income taxes | $1,132 · +5.2% |
| Income Tax Benefit | $75 |
| Earnings from discontinued operations, net of income taxes | $28 · vs $0 |
| Net earnings | $1,235 · +36.0% · $1.75/sh · 18.8% margin |
Verdict: Danaher's Q3 2026 sales rose 8.3% to $6,554 million and operating profit grew 7.9% to $1,245 million. Net earnings jumped 36.0% to $1,235 million, or $1.75 per diluted share versus $1.27.
Danaher raised its full-year 2026 adjusted diluted EPS guidance to $8.57–$8.62 from $8.45–$8.60. For Q4 2026 it expects non-GAAP core revenue excluding respiratory to grow 4.0%–5.0% and core revenue to grow about 3.0%. Q3 operating cash flow was $1.9 billion and free cash flow was $1.6 billion.
Source and notation
Source: Danaher press release, 8-K EX-99.1 of 10/21/2026 (SEC EDGAR).
Open as an image: Danaher Corporation (DHR), Q3 2026 (PNG) ↗ · for sharing and presentations · free to reuse, CC BY 4.0
Cite / embed this chart
Free to use in articles, research and social posts with credit to Who Reports Today and a link — licensed under CC BY 4.0 (terms).
Chart: “Danaher Corporation (DHR) Q3 2026: where the revenue went” by Who Reports Today, https://whoreportstoday.com/t/dhr. Licensed under CC BY 4.0.
<figure> <a href="https://whoreportstoday.com/t/dhr"><img src="https://whoreportstoday.com/t/dhr/img/danaher-dhr-earnings-sankey.png" alt="Danaher Corporation (DHR) Q3 2026: where the revenue went" loading="lazy" style="max-width:100%;height:auto"></a> <figcaption>Source: <a href="https://whoreportstoday.com/t/dhr">Who Reports Today</a>, licensed under <a href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0</a></figcaption> </figure>
https://whoreportstoday.com/t/dhr/img/danaher-dhr-earnings-sankey.png
<a href="https://whoreportstoday.com/t/dhr">Danaher Corporation (DHR) Q3 2026 earnings chart (Who Reports Today)</a>
The image link always shows the latest report’s chart and will update with the next quarter. To keep this exact chart in your article, save the PNG and upload it yourself — the license allows that. If you change the chart (crop, translate), say so in the credit. Company logos and trademarks are not covered by the license.
- Income taxes were a $75 million benefit versus a $168 million expense a year earlier.
- Interest expense nearly doubled to $135 million from $67 million; interest income was $31 million versus $3 million.
- Gross margin edged up to 58.5% from 58.2%, but operating margin slipped to 19.0% from 19.1%.
- Q3 included $513 million of amortization of acquisition-related intangibles versus $433 million, an $84 million inventory fair value adjustment and a $52 million facility impairment.
- Diluted EPS from continuing operations was $1.71 versus $1.27, and discontinued operations added $0.04 per share ($28 million).
- Diluted shares fell to 706.8 million from 713.7 million.
What distorts the picture in this report and what to watch beyond the headlines.
Who runs the company now
- Julie Sawyer MontgomeryPresident and Chief Executive Officer [1]
- Matthew GuginoExecutive Vice President and Chief Financial Officer [2]
As of 11/18/2026, per the company’s SEC filings: signatures on the latest report and leadership-change filings.
Positions and previous jobs: the company’s SEC filings. Spotted an error, or is this you and you’d like it corrected or removed? Contact us
Where they worked before
- Danahersince 2023
- Chief Executive Officersince 2026
- Executive Vice President2024–2026
- Vice President – Group Executive, Diagnostics2023–2024
- Beckman Coulter Diagnostics2020–2022President
Source: SEC EDGAR: 10-K annual report, 2026-02-24 · as of 10/21/2026
How this is compiled
Who runs the company now comes from primary sources only: for US and Canadian companies, the CEO and CFO signatures on the latest SEC report, and a separate board chair from the proxy materials; for Russian and Kazakh issuers, the company website and its disclosures. We recheck weekly; if a name can’t be confirmed, or a leadership-change filing came out after the report, we don’t show it until it’s reviewed. Previous jobs are only what the company itself disclosed about its current leaders (the past five years of business experience in the annual report and proxy materials): employer, position and years, restated as facts, with no age, education or other personal details. If the company doesn’t disclose it, we don’t look elsewhere. Anything more than 400 days past its last check is hidden. These are public business facts from disclosures, shown to tell investors who runs the company (our legitimate interest); if this is you and you object, contact us via the link above and we’ll remove it.
Sources · 2
- SEC EDGAR: 10-Q 2026-10-21 · SEC EDGAR · 11/18/2026
- SEC EDGAR: 10-Q 2026-10-21 · SEC EDGAR · 11/18/2026
Danaher Corporation is an American healthcare company headquartered in Washington, D.C.. It develops products used for advances in biotechnology, life sciences, and diagnostics. · Text: Wikipedia, CC BY-SA 4.0, abridged
The company operates three divisions: biotechnology, which develops products for the development of therapeutics; life sciences, which develops products to identify causes of disease, new therapies, and to test and manufacture new drugs, vaccines and gene editing technologies; and diagnostics, which develops instruments, consumables, and software and services to diagnose diseases. Danaher was founded in 1984 by brothers Steven Rales and Mitchell Rales; it was named after Danaher Creek in Western Montana, where the brothers came up with the idea for the company while fishing.
Company reports
Company guidance
| Period | Company guidance | A year ago | Implied growth |
|---|---|---|---|
| FY2026 | EPS (non-GAAP) $8.57–8.62 (raised) | revenue $24.57BEPS (GAAP) $5.05 | — |
Same quarter a year ago (ended December 31, 2025): revenue $6.84B, EPS (GAAP) $1.69
How we calculate
EPS growth is not calculated: the guidance is non-GAAP (adjusted), while the year-ago EPS is GAAP, so the two are not comparable.
Year-ago figures are GAAP, from the company's SEC filings (XBRL); EPS is diluted.
Guidance comes from the company's earnings release (Form 8-K filed Oct 21, 2026); every figure is checked against the release text.
DHR earnings history: past report dates
| Oct 21, 2026 Wed | before market open | Sep 25, 2026 | $6.6B+8% y/y | $1.75+38% y/y |
| Jul 21, 2026 Tue | before market open | Jun 26, 2026 | $6.3B+6% y/y | $1.23+60% y/y |
| Apr 21, 2026 Tue | before market open | Mar 27, 2026 | $6.0B+4% y/y | $1.45+10% y/y |
| Jan 12, 2026 Mon | 9:07 ambefore market open | Dec 31, 2025 | ≈$6.8B+5% y/y | ≈$1.69+13% y/y |
| Oct 21, 2025 Tue | before market open | Sep 26, 2025 | $6.1B+4% y/y | $1.27+13% y/y |
| Jul 22, 2025 Tue | before market open | Jun 27, 2025 | $5.9B+3% y/y | $0.77−37% y/y |
| Apr 22, 2025 Tue | 6:08 ambefore market open | Mar 28, 2025 | $5.7B−1% y/y | $1.32−9% y/y |
| Jan 13, 2025 Mon | 4:22 pmafter market close | Dec 31, 2024 | ≈$6.5B+2% y/y | ≈$1.50+3% y/y |
| Oct 22, 2024 Tue | before market open | Sep 27, 2024 | $5.8B+3% y/y | $1.12−26% y/y |
| Jul 23, 2024 Tue | before market open | Jun 28, 2024 | $5.7B−3% y/y | $1.22−18% y/y |
| Apr 23, 2024 Tue | before market open | Mar 29, 2024 | $5.8B−3% y/y | $1.45−25% y/y |
| Jan 8, 2024 Mon | 4:22 pmafter market close | Dec 31, 2023 | $6.4B−10% y/y | $1.45−52% y/y |
| Oct 24, 2023 Tue | before market open | Sep 29, 2023 | $5.6B−13% y/y | $1.51−28% y/y |
Show all 13 reports since 2023Show fewer
How we count
Report date and time — when the company filed its results press release with the SEC (Form 8-K, Item 2.02); the regular session runs 9:30 am – 4:00 pm ET. Companies that file the 8-K late in the evening publish the release the next morning: the date is that morning, before market open, and the evening filing time is not shown. Revenue and diluted EPS — the company’s XBRL filings, EPS adjusted for stock splits; ≈ — fourth quarter derived as full year minus three quarters. Source: SEC EDGAR.
Danaher Corporation: 15-year financials
| 2025 | 24,568 | 4,690 | 3,614 | 5,260 | 878 |
| 2024 | 23,875 | 4,863 | 3,899 | 5,296 | 768 |
| 2023 | 23,890 | 5,202 | 4,764 | 5,781 | 821 |
| 2022 | 26,643 | 7,536 | 7,209 | 7,401 | 818 |
| 2021 | 24,802 | 6,377 | 6,433 | 7,118 | 742 |
| 2020 | 22,284 | 4,231 | 3,646 | 5,417 | 615 |
| 2019 | 17,911 | 3,269 | 3,008 | 3,316 | 527 |
| 2018 | 19,893 | 3,055 | 2,651 | 3,438 | 433 |
| 2017 | 18,330 | 2,572 | 2,492 | 2,907 | 378 |
| 2016 | 16,882 | 2,735 | 2,554 | 2,932 | 400 |
| 2015 | 14,434 | 2,162 | 3,357 | 3,289 | 354 |
| 2014 | 12,867 | 2,045 | 2,598 | 3,293 | 228 |
| 2013 | 18,283 | 3,121 | 2,695 | 3,047 | 52.1 |
| 2012 | 18,260 | 3,165 | 2,392 | 2,957 | 86.4 |
| 2011 | 16,091 | 2,617 | 2,172 | 2,292 | 61.3 |
$ millions, annual 10-K reports on SEC EDGAR (US GAAP)*.
How we calculate
Figures are annual report lines; if a year was later restated (discontinued operations, mergers), we use the latest filing that shows it. Free cash flow is operating cash flow minus capital expenditures; dividends are cash paid to common shareholders during the year. “—” means the line isn’t in the filing. The table starts in 2011; where the listed issuer changed (holding reorganization, redomicile), earlier years come from the predecessor’s filings.
Danaher Corporation: 15-year balance sheet
| Year | Assets | Equity | Debt | Cash | Current assets | Current liabilities |
|---|---|---|---|---|---|---|
| 2025 | 83,464 | 52,534 | 18,418 | 4,615 | 12,756 | 6,807 |
| 2024 | 77,542 | 49,543 | 16,005 | 2,078 | 9,497 | 6,798 |
| 2023 | 84,488 | 53,486 | 18,402 | 5,864 | 13,937 | 8,274 |
| 2022 | 84,350 | 50,082 | 19,677 | 5,995 | 15,883 | 8,389 |
| 2021 | 83,184 | 45,167 | 22,176 | 2,586 | 11,648 | 8,140 |
| 2020 | 76,161 | 39,766 | 21,204 | 6,035 | 13,802 | 7,402 |
| 2019 | 62,082 | 30,271 | 21,729 | 19,912 | 25,596 | 4,932 |
| 2018 | 47,833 | 28,214 | 9,740 | 788 | 7,094 | 4,842 |
| 2017 | 46,649 | 26,358 | 10,522 | 630 | 6,850 | 4,792 |
| 2016 | 45,295 | 23,003 | 12,269 | 964 | 6,665 | 6,874 |
| 2015 | 48,222 | 23,690 | 12,870 | 791 | 7,837 | 6,170 |
| 2014 | 36,992 | 23,378 | 4,238 | 3,006 | 9,431 | 5,396 |
| 2013 | 34,672 | 22,385 | 3,949 | 3,115 | 9,114 | 4,527 |
| 2012 | 32,941 | 19,017 | 6,568 | 1,679 | 7,588 | 4,206 |
| 2011 | 29,950 | 16,905 | 6,283 | 537 | 6,272 | 4,172 |
$ millions, at fiscal year-end*.
* Sources
How we calculate
Annual balance sheet figures. “—” means no data; zero appears only when a numeric zero is present. Metrics with fewer than two values are omitted. Annual amounts use the financial screener data, in the reporting currency. Equity is attributable to shareholders where available, otherwise total equity including noncontrolling interests. Debt and cash follow the stored figures: they may include leases and restricted cash. Snapshot updated: .
Cash flow, 8 years
| Year | CFO · Operating cash flow | CAPEX · Capital expenditure | FCF · Free cash flowcalculated | FCF margin, %calculated | Dividends paid | FCF / net income, %calculated | CFI · Investing cash flow | CFF · Financing cash flow |
|---|---|---|---|---|---|---|---|---|
| 20252025-12-31 | 6,416 | — | — | — | — | — | −1,196 | −2,961 |
| 20242024-12-31 | 6,688 | — | — | — | — | — | −1,981 | −8,385 |
| 20222022-12-31 | — | — | — | — | — | — | — | −2,570 |
| 20212021-12-31 | — | — | — | — | — | — | — | 1,295 |
| 20182018-12-31 | — | — | — | — | — | — | — | −797 |
| 20172017-12-31 | — | — | — | — | — | — | — | −3,099 |
| 20152015-12-31 | — | — | — | — | — | — | — | 9,050 |
| 20142014-12-31 | — | — | — | — | — | — | — | −218 |
More detailsHide details
$ millions, per fiscal year; ratios in %. “—” — no verified data or calculation not applicable.
How we calculate
CFO, CFI and CFF are net operating, investing and financing cash flows. CAPEX is a positive cash outflow for capital expenditure; its scope follows the issuer document line. FCF = CFO − CAPEX; lease repayments are not deducted separately. If no separately sourced numeric CAPEX amount is available, CAPEX and FCF calculations are omitted. FCF margin = FCF / same-year revenue × 100. FCF / net income = FCF / same-year income attributable to shareholders × 100; losses or zero income produce a dash. Revenue and income use this card’s indicators table; missing or mismatched periods produce no ratio. Dividends and common share buybacks are actual annual cash payments from the cash flow statement, shown as positive cash outflows; payments to noncontrolling interests and share-compensation withholding taxes are excluded. Zero requires document evidence. Buybacks appear only if at least one reviewed payment exists in the fifteen-year window. The window is fifteen years; years without a single value are omitted. All listed years stay open; CFI, CFF and buybacks for Russia and Kazakhstan appear under More details.
Snapshot reviewed: . Updated after annual filings and three checks against issuer documents. Unreviewed and interim periods are excluded from the annual series.
More: latest reported period
9 months ended 2026-09-25 · $M
| Line | This period | Year ago | Δ |
|---|---|---|---|
| Operating cash flowcash the business generated | 4,742 | 4,299 | +443 |
| · incl. D&A (non-cash add-back)depreciation & amortization | 597 | 555 | |
| · incl. stock-based comp (non-cash)share-based compensation | 266 | 235 | |
| Capexpurchases of property & equipment | −761 | −785 | +24 |
| Free cash flow ≈operating cash flow − capex | 3,981 | 3,514 | +467 |
| Investing activities, netcapex, acquisitions, securities | −10,696 | −812 | −9,884 |
| · incl. acquisitionsbusinesses net of cash acquired | −9,881 | 0 | −9,881 |
| Financing activities, netdebt, buybacks, dividends | 7,057 | −4,283 | +11,340 |
| · incl. buybacksrepurchases of common stock | −894 | −3,088 | +2,194 |
| · incl. dividends paid | −790 | −652 | −138 |
| FX effect on cash | −36 | 246 | −282 |
| Net change in cash | 1,067 | −550 | +1,617 |
Cash flow is cumulative from the start of the fiscal year, rather than a single quarter. Lines marked ≈ are derived. Green Δ means more cash in (or less out) than a year ago. ≈ in Δ means a difference that rounds to zero at the displayed precision.
Shareholders’ equity at Sep 25, 2026: $53.6B (58% of total assets). Compare with other S&P 500 companies →
Corporate governance
2/2good
- Feb 202610-K cover: a single registered class of common stock (Common stock, $0.01), NYSE. sec.gov ↗
- Feb 2026Diluted share count −0.4% over 2020–2025; SBC of $298M = 1.2% of revenue; buybacks of $6.0B in 2024 and $3.1B in 2025 (XBRL). data.sec.gov ↗
2 more facts and scoring
How the company treats minority shareholders: 2 — well, 0 — systematically poorly.
- Jan 2026The quarterly dividend was raised to $0.32 per share; dividend payments of $878M in 2025 versus $768M in 2024. sec.gov ↗
- Aug 2025Class action Hawkins v. Danaher (2023) over bioprocessing revenue guidance: the court partly denied the motion to dismiss, the case is unresolved; the 10-K lists no other shareholder suits or SEC cases. sec.gov ↗
Scoring: 2.0 with no deductions = 2.0 (single share class, no dilution, dividends rising, Hawkins suit unresolved, no SEC cases)
- Share classes
- Single class of common stock (10-K cover: Common stock, NYSE).
- Dilution
- Diluted shares −0.4% over 2020–2025 (MCPS preferred conversion included), SBC 1.2% of revenue; buybacks of $6.0B (2024) and $3.1B (2025).
- Disclosure
- Full 10-K/10-Q reporting.
- Dividends
- Quarterly dividend rising, raised to $0.32 in 2025; no cuts.
- Lawsuits & regulators
- Class action Hawkins v. Danaher (D.D.C., 2023) over bioprocessing guidance partly survived the motion to dismiss (Aug. 2025), unresolved → no deduction; no SEC cases.
- Related parties
- The Rales brothers (directors, ~10%) receive a fixed $419K salary with no bonus; agreements for servicing their aircraft on a cost-reimbursement basis — immaterial.
How the score works · checked as of Oct 2026
Included in screener lists: S&P 500 companies that paid dividends 10 years without a gap
Danaher Corporation (DHR) earnings: FAQ
When is DHR's next earnings date?
We have not yet seen an announcement of the date from Danaher Corporation (DHR). Based on last year's report on Jan 28, 2026, the next report is expected around Jan 27, 2027.
What time does DHR report earnings?
Danaher Corporation usually reports before market open: its latest results release came out on Oct 21, 2026 (the Form 8-K reached the SEC at 5:43 pm ET the evening before).
When did DHR last report earnings?
Danaher Corporation reported Q3 2026 results on Oct 21, 2026.
What has Danaher Corporation guided for FY2026?
Company guidance for FY2026: EPS (non-GAAP) $8.57–8.62 (raised). A year ago (FY2025): revenue $24.57B, EPS (GAAP) $5.05. Source: the company's earnings release (Form 8-K filed Oct 21, 2026).
Where can I find Danaher Corporation's financial statements?
On SEC EDGAR: quarterly reports (10-Q), the annual report (10-K) and earnings releases (8-K). The “Verified” badge next to the chart links to DHR's filings; this page breaks the latest report down in a Sankey chart.
What was DHR's net income in Q3 2026?
Danaher Corporation reported net income of $1,235M for Q3 2026 (+36.0% year over year), under US GAAP.
Does Danaher Corporation pay dividends?
Yes. In 2025, Danaher Corporation paid $878M in dividends on its common stock, per its 10-K. Earlier years are in the 15-year table above.
How has Danaher Corporation's revenue changed since 2011?
Per its 10-K filings, revenue grew 1.5x: $16,091M in 2011 and $24,568M in 2025. The peak was $26,643M in 2022. Year-by-year figures are in the table above.
New to earnings reports? Start with how to read an earnings report.
Get it every Monday: who reports this week
Once a week: companies that announced report dates for the week ahead (US and Canada), fresh report breakdowns with charts. Free, no account needed.
More reports: DVA · Q3 2026 · DXCM · Q3 2026 · ELV · Q3 2026 · EW · Q2 2026 · GEHC · Q3 2026 · GILD · Q3 2026 · HCA · Q3 2026 · HSIC · Q3 2026 · HUM · Q2 2026 · IDXX · Q3 2026 · all reports